Eintrag weiter verarbeiten
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects: Advantages and Controversial Aspects
Gespeichert in:
| Zeitschriftentitel: | Annals of the New York Academy of Sciences |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Annals of the New York Academy of Sciences, 1110, 2007, 1, S. 474-484 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
TOGNON, S. GRAZIANI, G. MARCOLONGO, R. TOGNON, S. GRAZIANI, G. MARCOLONGO, R. |
|---|---|
| author |
TOGNON, S. GRAZIANI, G. MARCOLONGO, R. |
| spellingShingle |
TOGNON, S. GRAZIANI, G. MARCOLONGO, R. Annals of the New York Academy of Sciences Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects History and Philosophy of Science General Biochemistry, Genetics and Molecular Biology General Neuroscience |
| author_sort |
tognon, s. |
| spelling |
TOGNON, S. GRAZIANI, G. MARCOLONGO, R. 0077-8923 1749-6632 Wiley History and Philosophy of Science General Biochemistry, Genetics and Molecular Biology General Neuroscience http://dx.doi.org/10.1196/annals.1423.050 <jats:p><jats:bold><jats:sc>Abstract</jats:sc>: </jats:bold> <jats:bold>Behcet's disease (BD) is a chronic, relapsing, multisystem disease. In some patients, ocular involvement can lead to severe vision impairment despite immunosuppressive therapy. Since high levels of circulating TNF‐α have been found both in peripheral blood and aqueous humor of patients with active BD, we evaluated the efficacy of anti‐TNF‐α therapy in seven patients with severe ocular involvement resistant to previous treatment. Seven patients with sight‐threatening relapsing uveitis refractory to immunosuppressive regimens received intravenously infliximab, at a dose of 3–5 mg/kg, on week 0–2–4 and then every 6–8 weeks, in combination with low‐dose prednisone and methotrexate or azathioprine. Efficacy was assessed in terms of number and severity of relapses of posterior uveitis, visual acuity, and reduction of corticosteroids and immunosuppressive drugs. After a mean follow‐up period of 23 months, the total number of relapses dropped to 6, compared to the 21 observed in an equivalent period of time before treatment. The visual acuity improved in 4 eyes, while it remained stable in 9. Therapy with infliximab considerably reduced the required daily dose of both corticosteroids and immunosuppressive drugs. In our experience infliximab proved to be safe and effective in controlling both the number and intensity of cases of posterior uveitis and the extraocular manifestations of BD. It also allowed a reduction of corticosteroids and immunosuppressive drugs required to control the disease. However, ocular and systemic manifestations tended to recur after drug withdrawal or when the interval between infliximab courses was longer than 8 weeks. Moreover, infliximab administration is costly and requires hospital admission.</jats:bold> </jats:p> Advantages and Controversial Aspects Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects Annals of the New York Academy of Sciences |
| doi_str_mv |
10.1196/annals.1423.050 |
| facet_avail |
Online |
| finc_class_facet |
Geschichte Philosophie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE5Ni9hbm5hbHMuMTQyMy4wNTA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE5Ni9hbm5hbHMuMTQyMy4wNTA |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 |
| imprint |
Wiley, 2007 |
| imprint_str_mv |
Wiley, 2007 |
| issn |
0077-8923 1749-6632 |
| issn_str_mv |
0077-8923 1749-6632 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
tognon2007antitnfatherapyinsevenpatientswithbehcetsuveitisadvantagesandcontroversialaspectsadvantagesandcontroversialaspects |
| publishDateSort |
2007 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Annals of the New York Academy of Sciences |
| source_id |
49 |
| title_sub |
Advantages and Controversial Aspects |
| title |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_unstemmed |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_full |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_fullStr |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_full_unstemmed |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_short |
Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_sort |
anti‐tnf‐α therapy in seven patients with behçet's uveitis : advantages and controversial aspects |
| topic |
History and Philosophy of Science General Biochemistry, Genetics and Molecular Biology General Neuroscience |
| url |
http://dx.doi.org/10.1196/annals.1423.050 |
| publishDate |
2007 |
| physical |
474-484 |
| description |
<jats:p><jats:bold><jats:sc>Abstract</jats:sc>: </jats:bold> <jats:bold>Behcet's disease (BD) is a chronic, relapsing, multisystem disease. In some patients, ocular involvement can lead to severe vision impairment despite immunosuppressive therapy. Since high levels of circulating TNF‐α have been found both in peripheral blood and aqueous humor of patients with active BD, we evaluated the efficacy of anti‐TNF‐α therapy in seven patients with severe ocular involvement resistant to previous treatment. Seven patients with sight‐threatening relapsing uveitis refractory to immunosuppressive regimens received intravenously infliximab, at a dose of 3–5 mg/kg, on week 0–2–4 and then every 6–8 weeks, in combination with low‐dose prednisone and methotrexate or azathioprine. Efficacy was assessed in terms of number and severity of relapses of posterior uveitis, visual acuity, and reduction of corticosteroids and immunosuppressive drugs. After a mean follow‐up period of 23 months, the total number of relapses dropped to 6, compared to the 21 observed in an equivalent period of time before treatment. The visual acuity improved in 4 eyes, while it remained stable in 9. Therapy with infliximab considerably reduced the required daily dose of both corticosteroids and immunosuppressive drugs. In our experience infliximab proved to be safe and effective in controlling both the number and intensity of cases of posterior uveitis and the extraocular manifestations of BD. It also allowed a reduction of corticosteroids and immunosuppressive drugs required to control the disease. However, ocular and systemic manifestations tended to recur after drug withdrawal or when the interval between infliximab courses was longer than 8 weeks. Moreover, infliximab administration is costly and requires hospital admission.</jats:bold> </jats:p> |
| container_issue |
1 |
| container_start_page |
474 |
| container_title |
Annals of the New York Academy of Sciences |
| container_volume |
1110 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334402657714179 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:28:05.204Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Anti%E2%80%90TNF%E2%80%90%CE%B1+Therapy+in+Seven+Patients+with+Beh%C3%A7et%27s+Uveitis+%3A+Advantages+and+Controversial+Aspects&rft.date=2007-09-01&genre=article&issn=1749-6632&volume=1110&issue=1&spage=474&epage=484&pages=474-484&jtitle=Annals+of+the+New+York+Academy+of+Sciences&atitle=Anti%E2%80%90TNF%E2%80%90%CE%B1+Therapy+in+Seven+Patients+with+Beh%C3%A7et%27s+Uveitis+%3A+Advantages+and+Controversial+Aspects&aulast=MARCOLONGO&aufirst=R.&rft_id=info%3Adoi%2F10.1196%2Fannals.1423.050&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334402657714179 |
| author | TOGNON, S., GRAZIANI, G., MARCOLONGO, R. |
| author_facet | TOGNON, S., GRAZIANI, G., MARCOLONGO, R., TOGNON, S., GRAZIANI, G., MARCOLONGO, R. |
| author_sort | tognon, s. |
| container_issue | 1 |
| container_start_page | 474 |
| container_title | Annals of the New York Academy of Sciences |
| container_volume | 1110 |
| description | <jats:p><jats:bold><jats:sc>Abstract</jats:sc>: </jats:bold> <jats:bold>Behcet's disease (BD) is a chronic, relapsing, multisystem disease. In some patients, ocular involvement can lead to severe vision impairment despite immunosuppressive therapy. Since high levels of circulating TNF‐α have been found both in peripheral blood and aqueous humor of patients with active BD, we evaluated the efficacy of anti‐TNF‐α therapy in seven patients with severe ocular involvement resistant to previous treatment. Seven patients with sight‐threatening relapsing uveitis refractory to immunosuppressive regimens received intravenously infliximab, at a dose of 3–5 mg/kg, on week 0–2–4 and then every 6–8 weeks, in combination with low‐dose prednisone and methotrexate or azathioprine. Efficacy was assessed in terms of number and severity of relapses of posterior uveitis, visual acuity, and reduction of corticosteroids and immunosuppressive drugs. After a mean follow‐up period of 23 months, the total number of relapses dropped to 6, compared to the 21 observed in an equivalent period of time before treatment. The visual acuity improved in 4 eyes, while it remained stable in 9. Therapy with infliximab considerably reduced the required daily dose of both corticosteroids and immunosuppressive drugs. In our experience infliximab proved to be safe and effective in controlling both the number and intensity of cases of posterior uveitis and the extraocular manifestations of BD. It also allowed a reduction of corticosteroids and immunosuppressive drugs required to control the disease. However, ocular and systemic manifestations tended to recur after drug withdrawal or when the interval between infliximab courses was longer than 8 weeks. Moreover, infliximab administration is costly and requires hospital admission.</jats:bold> </jats:p> |
| doi_str_mv | 10.1196/annals.1423.050 |
| facet_avail | Online |
| finc_class_facet | Geschichte, Philosophie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE5Ni9hbm5hbHMuMTQyMy4wNTA |
| imprint | Wiley, 2007 |
| imprint_str_mv | Wiley, 2007 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161 |
| issn | 0077-8923, 1749-6632 |
| issn_str_mv | 0077-8923, 1749-6632 |
| language | English |
| last_indexed | 2024-03-01T14:28:05.204Z |
| match_str | tognon2007antitnfatherapyinsevenpatientswithbehcetsuveitisadvantagesandcontroversialaspectsadvantagesandcontroversialaspects |
| mega_collection | Wiley (CrossRef) |
| physical | 474-484 |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Annals of the New York Academy of Sciences |
| source_id | 49 |
| spelling | TOGNON, S. GRAZIANI, G. MARCOLONGO, R. 0077-8923 1749-6632 Wiley History and Philosophy of Science General Biochemistry, Genetics and Molecular Biology General Neuroscience http://dx.doi.org/10.1196/annals.1423.050 <jats:p><jats:bold><jats:sc>Abstract</jats:sc>: </jats:bold> <jats:bold>Behcet's disease (BD) is a chronic, relapsing, multisystem disease. In some patients, ocular involvement can lead to severe vision impairment despite immunosuppressive therapy. Since high levels of circulating TNF‐α have been found both in peripheral blood and aqueous humor of patients with active BD, we evaluated the efficacy of anti‐TNF‐α therapy in seven patients with severe ocular involvement resistant to previous treatment. Seven patients with sight‐threatening relapsing uveitis refractory to immunosuppressive regimens received intravenously infliximab, at a dose of 3–5 mg/kg, on week 0–2–4 and then every 6–8 weeks, in combination with low‐dose prednisone and methotrexate or azathioprine. Efficacy was assessed in terms of number and severity of relapses of posterior uveitis, visual acuity, and reduction of corticosteroids and immunosuppressive drugs. After a mean follow‐up period of 23 months, the total number of relapses dropped to 6, compared to the 21 observed in an equivalent period of time before treatment. The visual acuity improved in 4 eyes, while it remained stable in 9. Therapy with infliximab considerably reduced the required daily dose of both corticosteroids and immunosuppressive drugs. In our experience infliximab proved to be safe and effective in controlling both the number and intensity of cases of posterior uveitis and the extraocular manifestations of BD. It also allowed a reduction of corticosteroids and immunosuppressive drugs required to control the disease. However, ocular and systemic manifestations tended to recur after drug withdrawal or when the interval between infliximab courses was longer than 8 weeks. Moreover, infliximab administration is costly and requires hospital admission.</jats:bold> </jats:p> Advantages and Controversial Aspects Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects Annals of the New York Academy of Sciences |
| spellingShingle | TOGNON, S., GRAZIANI, G., MARCOLONGO, R., Annals of the New York Academy of Sciences, Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects, History and Philosophy of Science, General Biochemistry, Genetics and Molecular Biology, General Neuroscience |
| title | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_full | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_fullStr | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_full_unstemmed | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_short | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| title_sort | anti‐tnf‐α therapy in seven patients with behçet's uveitis : advantages and controversial aspects |
| title_sub | Advantages and Controversial Aspects |
| title_unstemmed | Anti‐TNF‐α Therapy in Seven Patients with Behçet's Uveitis : Advantages and Controversial Aspects |
| topic | History and Philosophy of Science, General Biochemistry, Genetics and Molecular Biology, General Neuroscience |
| url | http://dx.doi.org/10.1196/annals.1423.050 |